Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis-Reference-Cited by-同舟云学术

Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis

Published:2013-02-28 Issue:4 Volume:88 Page:312-316
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol

Author:

Pardanani Animesh¹²,Finke Christy¹²,Abdelrahman Ramy A.¹²,Lasho Terra L.¹²,Tefferi Ayalew¹²

Affiliation:

1. Division of Hematology; Mayo Clinic; Rochester Minnesota

2. Department of Medicine; Mayo Clinic; Rochester Minnesota

Publisher

Wiley

Subject

Hematology

Reference21 articles.

1. One thousand patients with primary myelofibrosis: The mayo clinic experience;Tefferi;Mayo Clin Proc,2012

2. Circulating interleukin (IL)−8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study;Tefferi;J Clin Oncol,2011

3. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis;Verstovsek;N Engl J Med,2010

4. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy;Leitch;Hematol Oncol,2010

5. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis;Winder;Br J Haematol,2008

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Momelotinib: Mechanism of action, clinical, and translational science;Clinical and Translational Science;2024-08

2. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02

3. Targeting anemia in myeloid neoplasms;American Journal of Hematology;2024-06-05

4. Momelotinib in myelofibrosis;Expert Opinion on Pharmacotherapy;2024-03-23

5. Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials;HemaSphere;2023-10-27